Ocuphire Pharma Results

Intravitreal Injections Landscape (DR patients) Eylea/Lucentis Approved, But Not Used in Patients with Mild NPDR and Mild PDR Company REGENERON Roche KODIAK EYEPOINT PHARMACEUTICALS Boehringer Ingelheim Therapeutix REGENXBIO Drug Eylea (aflibercept) Ocuphire Company websites; www.clinicaltrials.gov PHARMA Lucentis (ranibizumab) VEGF-A KSI-301 (Tarcocimab) EYP-1901 BI 764524 OTX-TKI Target/MOA RGX-314 VEGF-A/B; PIGF VEGF Voloronib (TKI) Anti-Sema3A Ischemia modulator Axitinib (TKI) AAV8-VEGF Route of Administration Intravitreal Intravitreal Intravitreal Intravitreal Intravitreal Intravitreal Suprachoroidal (Gene Therapy) ✓ Completed Phase 1 Phase 2 Phase 3 Commercial ✓ ✓ ✓ Ongoing N/A ✓*1 ✓*2 *Trials to Support Approval 1 Panorama Clinical Trial 2 Protocol I & T and Rise & Ride X Discontinued or Failed study 26

View entire presentation